Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Immanuel Luescher

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Journal of Biological Chemistry|May 3, 2012
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsivenessMelita Irving, Vincent Zoete, Michael Hebeisen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cellsMikaël J Pittet, Verena Rubio-Godoy, Gilles Bioley, et al.
International Journal of Cancer|June 26, 2012
Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptideShingo Eikawa, Kazuhiro Kakimi, Midori Isobe, et al.
Plos One|August 11, 2011
NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartmentNassima Redjimi, Karine Duperrier-Amouriaux, Isabelle Raimbaud, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 25, 2010
Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cellsDaisuke Muraoka, Takuma Kato, Linan Wang, et al.
Biochemistry|March 10, 2021
Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass SpectrometryPatrick S Merkle, Esben Trabjerg, Song Hongjian, et al.
Biochemistry|July 4, 2017
The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β<sub>2</sub>-Microglobulin through Distinct Binding SitesPatrick S Merkle, Melita Irving, Song Hongjian, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 4, 2006
Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1Heather Jackson, Nektaria Dimopoulos, Nicole A Mifsud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2015
Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical TrialAmandine Legat, Hélène Maby-El Hajjami, Petra Baumgaertner, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Journal of Biological Chemistry|May 3, 2012
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsivenessMelita Irving, Vincent Zoete, Michael Hebeisen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cellsMikaël J Pittet, Verena Rubio-Godoy, Gilles Bioley, et al.
International Journal of Cancer|June 26, 2012
Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptideShingo Eikawa, Kazuhiro Kakimi, Midori Isobe, et al.
Plos One|August 11, 2011
NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartmentNassima Redjimi, Karine Duperrier-Amouriaux, Isabelle Raimbaud, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 25, 2010
Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cellsDaisuke Muraoka, Takuma Kato, Linan Wang, et al.
Biochemistry|March 10, 2021
Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass SpectrometryPatrick S Merkle, Esben Trabjerg, Song Hongjian, et al.
Biochemistry|July 4, 2017
The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β<sub>2</sub>-Microglobulin through Distinct Binding SitesPatrick S Merkle, Melita Irving, Song Hongjian, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 4, 2006
Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1Heather Jackson, Nektaria Dimopoulos, Nicole A Mifsud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2015
Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical TrialAmandine Legat, Hélène Maby-El Hajjami, Petra Baumgaertner, et al.
Pageof 3